MarginsXMarginsX
Home › Markets › Health Care › MXCT

MaxCyte Inc. (MXCT)

MXCT trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.18
-0.84% on the day
Market cap
$121.8M
Micro cap
Revenue · 2025
$33.0M
-14.5% on 2024
Net income · 2025
-$44.6M
-135.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1287098/000110465926034557/0001104659-26-034557-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMXCT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO year2021
SEC CIK0001287098
SEC industry codeServices-Commercial Physical & Biological Research
Incorporated inDE

Financials · 2025

LineValue
Revenue$33.0M
Net income-$44.6M
Operating income-$51.9M
Net margin-135.1%
Operating margin-157.1%
Revenue growth-14.5%
Cash$20.1M
Total assets$202.5M
P/E (computed)Net income was not positive
P/S (computed)3.7×

Warning signs

Cash runway
7.6 months
$13.4M cash at September 30, 2026
Share count, 1 year
-3.2%
2025-11-07 to 2026-11-06 · -0.3% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$8K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$13.4M cash; operating cash flow -$5.3M a quarter.Report 2026-09-30
Shares outstanding103,250,292 (2026-11-06); 106,674,011 a year earlier; 103,576,429 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-03-20
AuditorCohnReznick LLP, Tysons, Virginia, United StatesPCAOB Form AP 2026-04-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $8K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$10.2M-$4.8M-$5.5M$13.4MNo debt tags$34.4M10-Q 2026-11-10
Q2 2026
2026-06-30
$7.3M-$8.9M-$4.7M$15.0MNo debt tags$31.1M10-Q 2026-08-13
Q1 2026
2026-03-31
$9.7M-$4.8M-$8.2M$14.6MNo debt tags$32.3M10-Q 2026-05-13
Q4 2025
2025-12-31
$7.3M-$9.6M-$2.7M$20.1MNo debt tags$33.0M10-K 2026-03-25
Q3 2025
2025-09-30
$6.8M-$12.4M-$7.5M$13.0MNo debt tags$34.4M10-Q 2026-11-10
Q2 2025
2025-06-30
$8.5M-$12.4M-$9.9M$15.2MNo debt tags$35.8M10-Q 2026-08-13
Q1 2025
2025-03-31
$10.4M-$10.3M-$14.4M$23.4MNo debt tags$37.7M10-Q 2026-05-13
Q4 2024
2024-12-31
$8.7M-$10.6M-$7.8M$27.9MNo debt tags$38.6M10-K 2026-03-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42021-07-30
Latest annual report10-K2026-03-25
Latest quarterly / interim10-Q2026-11-10
Latest current report
FORM 8-K
8-K2026-11-10
Latest proxy
DEFA 14A
DEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 338 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.6%
1 month+23.4%
3 months-14.4%
Year to date-23.2%
1 year-21.2%
From 52-week high-32.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
ONMDOneMedNet Corp$4.86-8.99%$29.2M
NRCNRC Health$26.33-0.87%$558.8M
OABIOmniAb Inc.$4.89-0.41%$713.3M
ABSIAbsci Corporation$7.47-11.54%$1.3B
BIAFbioAffinity Technologies Inc.$2.00-9.09%$3.6M
ISPCiSpecimen Inc.$0.6049-8.17%$3.3M
ICLRICON plc$191.40-1.67%$14.7B
CRLCharles River Laboratories International Inc.$335.52-0.72%$16.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier